In this free webinar, gain insights into an overview of adaptive immune response in narcolepsy. The featured speaker will discuss determining peptide binding affinity to human leukocyte antigen (HLA). The speaker will also share insights into isolating antigen-HLA-restricted CD4+ T cells using tetramer HLA. Attendees will also learn about single-cell RNA sequencing of CD4+ T cells and cerebrospinal fluid (CSF).
TORONTO, Sept. 27, 2023 /PRNewswire-PRWeb/ -- Narcolepsy — a chronic neurological disorder — affects the brain's capability in controlling the sleep-wake cycles. People affected with narcolepsy might feel rested after waking up, but then feel very sleepy throughout the day. Most people with narcolepsy also experience interrupted and uneven sleep that can involve waking up repeatedly during the night.
There are two main types of narcolepsy: type 1 and type 2. Narcolepsy type 1 (NT1) is based on the patient either having low levels of a brain hormone — hypocretin — or having excessive daytime sleepiness on a special nap test and reporting cataplexy (a brain disorder where there is a temporary and sudden loss of brain muscle tone and control).
People with narcolepsy type 2 experience extreme daytime sleepiness but usually don't experience muscle weakness activated by emotions. These patients usually have lighter symptoms and normal levels of hypocretin.
In this webinar, the featured speaker will share and discuss the following:
- An overview of adaptive immune response in narcolepsy
- Determining peptide binding affinity to human leukocyte antigen (HLA)
- Isolating antigen-HLA restricted CD4+ T cells using tetramer HLA
- Single-cell RNA sequencing of CD4+ T cells and cerebrospinal fluid (CSF)
Join this webinar to gain insights on the overview of the adaptive immune response in narcolepsy type 1.
Join Dr. Guo Luo, Immunologist and Instructor, Stanford University School of Medicine, for the live webinar on Friday, October 6, 2023, at 1pm EDT (10am PDT).
For more information, or to register for this event, visit Adaptive Immune Response in Narcolepsy Type 1.
Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global life science, food and medical device community. Every year, thousands of industry practitioners (from life science, food and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.